Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $74.6 million.

  • Entrada Therapeutics' Non-Current Assets fell 16.37% to $74.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.6 million, marking a year-over-year decrease of 16.37%. This contributed to the annual value of $86.3 million for FY2024, which is 13.22% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Non-Current Assets stood at $74.6 million, which was down 6.27% from $79.6 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Non-Current Assets ranged from a high of $103.8 million in Q2 2023 and a low of $39.7 million during Q3 2022.
  • Its 3-year average for Non-Current Assets is $86.3 million, with a median of $89.3 million in 2024.
  • Per our database at Business Quant, Entrada Therapeutics' Non-Current Assets surged by 156.71% in 2023 and then declined by 16.37% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Non-Current Assets stood at $42.2 million in 2022, then skyrocketed by 135.70% to $99.4 million in 2023, then dropped by 13.22% to $86.3 million in 2024, then decreased by 16.37% to $74.6 million in 2025.
  • Its Non-Current Assets stands at $74.6 million for Q3 2025, versus $79.6 million for Q2 2025 and $83.3 million for Q1 2025.